原发-转移病灶的RRM1和ERCC1表达差异性与非小细胞肺癌化疗疗效的相关性研究

Relationship between protein expression of ERCC1 and RRM1 in cancer tissues and lymph nodes and efficacy of platin-based chemotherapy in patient with non-small cell lung cancer

目的探讨癌组织及转移淋巴结内RRM1和ERCC1蛋白表达与非小细胞肺癌(non-small cell lung cancer,NSCLC)患者以铂类药物为基础化疗方案疗效的相关性。方法收集出现淋巴结转移的非小细胞肺癌术后患者临床资料100例,并用免疫组化检测癌组织、转移淋巴结标本及其相应的癌旁正常肺组织中的RRM1和ERCC1蛋白表达水平,并分析其与铂类药物为基础化疗方案敏感性的相关性。结果 (1)RRM1在癌组织(T)和转移淋巴结组织(N)中表达阳性率分别为58%和33%,ERCC1在癌组织(T)和转移淋巴结组织(N)中表达阳性率分别为56%和29%,差异均有统计学意义(P<0.05);(2)RRM1蛋白T(+)N(+)组化疗的有效率为13.3%(4/30),明显低于T(+)N(-)组的46.6%(13/28)以及T(-)N(-)组61.9%(26/42),差异具有统计学意义(P<0.05);ERCC1蛋白T(+)N(+)组化疗的有效率为17.2%(5/2 9),明显低于T(+)N(-)组的44.4%(12/27)以及T(-)N(-)组的61.4%(27/44),差异有统计学意义(P<0.05)。结论非小细胞肺癌患者RRM1和ERCC1在原发病灶与转移淋巴结表达的差异性是化疗方案中铂类药物敏感性差别的重要因素。

Objective To explore the relationship between protein expression of ERCC1 and RRM1 in cancer tissues and lymph nodes and efficacy of platin-based chemotherapy in patient with non-small cell lung cancer （NSCLC）. Methods 100 cases of non- small eel1 lung cancer with lymph node metastasis were collected. The ex- pression of ERCC1, RRM1 protein in cancer tissues and lymph nodes were detected with immunohistochemistry and its correlation with chemotherapy effect in patient with non- small cell lung cancer was analyzed. Results The posi- tive rate of ERCC1 expression in cancer tissue （T） and metastasis lymph node tissues （N） were 56% and 29%, and the positive rate of RRM1 expression in cancer tissue （T） and metastasis lymph node tissues （N） were 58% and 30% respectively （P 〉0. 05）. The effective rate of chemotherapy in the RRM1 T（ ＋ ） N（ ＋ ） group was 13.3% （4/30）, which was significantly lower than 46. 6% （13/28） in the T（ ＋ ） N（ - ） group and 61.9% （26/42） in the T（ - ） N（ - ） group （P 〈0. 05）. The effective rate of chemotherapy in the ERCC1 T（ ＋ ） N（ ＋ ） group was 17.2% （5/29）, which was significantly lower than 44.4% （12/27） in the T（ ＋ ） N（ - ） group and 61.4% （27/ 44） in the T（ - ） N （ - ） group （P 〈 O. 05 ）. Conclusion The difference of protein expression of ERCC1 and RRM1 in cancer tissues and lymph nodes is the important factor in the sensitivity of platinum drugs of chemotherapy, which may provide a reference for the clinical guide of individual chemotherapy for patients with NSCLC.